Neurocrine Biosciences Inc vs SMX Security Matters plc — how do they compare? Neurocrine Biosciences Inc trades at $142.68 (market cap $14.36B), while SMX Security Matters plc trades at $3.8 (market cap $4.13M). The key difference: Neurocrine Biosciences Inc is far larger — about 3477× SMX Security Matters plc's market cap, and Neurocrine Biosciences Inc is trading nearer its 52-week high, SMX Security Matters plc nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Neurocrine Biosciences Inc for 23 Days and SMX Security Matters plc for 21 Days on average.
| NBIX | SMX | |
|---|---|---|
Market Cap | $14.36B | $4.13M |
Volume | 1,237,180 | 124,362 |
Sector | Health | Industrials |
52-Week High | $185.50 | $74.08K |
52-Week Low | $123.10 | $3.79 |
Typical Hold Time | 23 Days | 21 Days |
Enterprise Value | $14.37B | -$27.20M |
Signals from Pluang's Aura AI — not financial advice
Neurocrine Biosciences (NBIX) trades at $141.69, down 1.24% on the day, with a bearish technical signal from moving averages. Fundamentally, the company shows strong profitability with a 20.91% net income margin and consistent earnings beats, including a significant Q2 2026 beat. Recent news highlights pipeline advancements and executive appointments, while analyst sentiment remains overwhelmingly positive.
The outlook for NBIX is supported by robust fundamentals and strong analyst buy ratings, but near-term price action is challenged by technical bearishness. Key opportunities include product diversification and pipeline growth, while risks involve execution of expansion plans and potential pricing pressures on key products like INGREZZA.
SMX trades at $4.21, up 7.95% today, but exhibits severe financial distress with no revenue, negative EBITDA of -$130.44M, and deeply negative ROE of -819.22% for 2025. The technical outlook is bearish based on moving averages, though oscillators like the RSI signal oversold conditions. Recent news highlights the company's focus on its Digital Material Passport platform for recycled plastics and material traceability, aiming to capitalize on circular economy trends.
The investment outlook is highly speculative. While the stock appears cheap on P/B (0.09) and EV/EBITDA (0.02) multiples, this reflects extreme financial losses and operational cash burn. Positive media coverage contrasts with the fundamental reality, creating significant risk. Upside depends entirely on the successful commercialization of its technology, which remains unproven given the current lack of revenue.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
No sentiment data available yet.
Latest headlines on both assets
Neurocrine Biosciences, Inc. is a biopharmaceutical company focused on discovering, developing, and commercializing innovative treatments for neurological, endocrine, and psychiatric disorders. The company's portfolio targets conditions such as tardive dyskinesia, endometriosis, and Parkinson's disease. NBIX leverages its expertise in neurobiology and small-molecule drug development to address diseases with significant unmet medical needs.
Read more on NBIX →SMX Security Matters plc is a digital authentication and tracking technology company that uses a chemical-based, invisible marker system to trace and verify products across global supply chains. Their technology creates a 'digital twin' of physical products, used for quality control, counterfeiting prevention, and ensuring sustainability compliance from raw materials to final sale. The company's solutions are applied across various industries, including precious materials, luxury goods, and fast-moving consumer goods.
Read more on SMX →